An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system
Cancer · 2025
DOI: 10.1002/cncr.35734 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer, 2025. Verfasst von Leah M Marcotte und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Black or African American, Breast Neoplasms, Early Detection of Cancer, Healthcare Disparities. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, AHRQ HHS, Agency for Healthcare Research and Quality.
Abstract (Originalsprache)
Background
Breast cancer screening (BCS) inequities are evident at national and local levels, and many health systems want to address these inequities, but may lack data about contributing factors. The objective of this study was to inform health system interventions through an exploratory analysis of potential multilevel contributors to BCS inequities using health system data.
Methods
The authors conducted a cross‐sectional analysis within a large academic health system including 19,774 individuals who identified as Black ( n = 1445) or White ( n = 18,329) race and were eligible for BCS. They evaluated individual‐level, provider‐level, and clinic‐level factors. They conducted logistic regression and Blinder‐Oaxaca (BO) decomposition analyses to quantitatively estimate the contribution of factors to the mean difference in BCS outcomes between the two racialized groups. They calculated average marginal effects (AME) for the logistic regression models representing the estimated additive probability of receiving BCS in the Black versus White group.
Results
BCS was completed in 63.7% of Black and 71.7% of White individuals (AME, –0.08; 95% confidence interval (CI), –0.10 to –0.04; p < .001). In the BO decomposition, observed factors explained 13.3% difference in BCS. Lower patient portal use among Black versus White patients had the greatest estimated contribution to the BCS inequity (4.6 percentage points; 95% CI, 3.0–6.2).
Conclusion
Racialized group differences in patient portal use had the greatest estimated contribution to the explained difference in BCS between Black and White individuals. Patient portal use promotion could be considered as a part of multifaceted health system efforts to address BCS inequities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
- Stanford Health Policy, Stanford University, Palo Alto, California, USA.
- General Medicine Service, VA Puget Sound Health Care System, Seattle, Washington, USA.
- Department of Medicine, University of Arizona, Tucson, Arizona, USA.
- Primary Care and Population Health, University of Washington Medicine, Seattle, Washington, USA.
- Population Health Analytics, University of Washington Medicine, Seattle, Washington, USA.
ORCID-Profile: Leah M Marcotte
Förderung
- NICHD NIH HHS
- AHRQ HHS
- Agency for Healthcare Research and Quality
Zitieren
APA
Marcotte, L. M., Khor, S., Reddy, A., Morenz, A., Nelson, K., Akinsoto, N., Lee, E. S., Onstad, S., & Wong, E. S. (2025). An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system. Cancer. https://doi.org/10.1002/cncr.35734
Vancouver
Marcotte LM, Khor S, Reddy A, Morenz A, Nelson K, Akinsoto N, et al. An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system. Cancer. 2025. doi:10.1002/cncr.35734
BibTeX
@article{Marcotte2025,
author = {Marcotte, Leah M and Khor, Sara and Reddy, Ashok and Morenz, Anna and Nelson, Karin and Akinsoto, Nkem and Lee, E Sally and Onstad, Susan and Wong, Edwin S},
title = {An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35734}
}
EUVIMED